A tale of 2 pneumococcal vaccines

Affiliations

Editorial

Keith P Klugman. Clin Infect Dis. 2014 Apr.

. 2014 Apr;58(7):925-7.

doi: 10.1093/cid/ciu007. Epub 2014 Feb 13.

No abstract available

Keywords: conjugate vaccine; empyema; pneumococcus; pneumonia; polysaccharide vaccine.

Comment on

Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, Craiu I, Zenkhri F, Dubos F, Guen CG, Launay E, Martinot A, Cohen R. Angoulvant F, et al. Clin Infect Dis. 2014 Apr;58(7):918-24. doi: 10.1093/cid/ciu006. Epub 2014 Feb 13. Clin Infect Dis. 2014. PMID: 24532543
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Ochoa-Gondar O, et al. Clin Infect Dis. 2014 Apr;58(7):909-17. doi: 10.1093/cid/ciu002. Epub 2014 Feb 13. Clin Infect Dis. 2014. PMID: 24532544